logo-loader
viewIndivior PLC

Respected medical journal publishes data from Indivior’s key Sublocade study

The phase III study, which was carried out back in 2017, was one of the key things FDA bosses looked at when approving Sublocade for use as an opioid addiction treatment

drug addict
Indivior wants Sublocade to replace falling sales of Suboxone – its under-pressure star asset

Prestigious medical journal The Lancet has published the results from a key study that served as the backbone for the US Food and Administration’s approval of Indivior PLC’s (LON:INDV) next-generation opioid addiction treatment, Sublocade.

The 504-person phase III trial, which was carried out in 2017, showed that addicts receiving Sublocade and counselling were far more likely to stop using opioids than those who were just receiving counselling.

READ: Indivior profits propped up by cost cuts

Sublocade was also found to better suppress cravings and withdrawal symptoms, while those using it were generally more satisfied with their medication than those on the placebo.

“These data show Sublocade can be effective in maintaining control of some barriers, making it an important treatment option for patients with moderate to severe opioid use disorder,” said Walter Ling from the University of California.

Sublocade is a once-monthly injection that Indivior hopes will take over from Suboxone – the company’s star asset which is facing severe competition from generic rivals.

It was approved at the end of 2018 and launched last year but has so far failed to live up to the initial hype, with doctors reluctant to prescribe it due to what Indivior called “friction in the new distribution and reimbursement model”.

Blockbuster potential

The injection had originally been expected to deliver sales of around US$100mln in 2018, but it only ended up bringing in US$12mln. Slough-based Indivior expects that to jump to between US$50-70mln in 2019.

That still leaves it well behind where it would have been expected to be at this stage, but bosses remain convinced that its status as a future blockbuster and potentially business-saving drug remains intact.

“The group is making good progress [with] the key performance indicators that it believes will drive accelerated net revenue growth for SUBLOCADE in pursuit of its US$1bn-plus peak net revenue goal,” said Indivior last week.

Indivior shares edged 0.3% higher to 118.7p at the opening bell on Tuesday.

Quick facts: Indivior PLC

Price: 41.5 GBX

LSE:INDV
Market: LSE
Market Cap: £303.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Impax Asset Management reveals key themes investors should...

Impax Asset Management Group PLC (LON:IPX) Head of Client Services and Business Development David Richardson tells Proactive key themes investors should look out for in 2020.  Richardson says he's seeing expansion in developing renewable energy projects in Europe, increased interested in...

1 day, 7 hours ago

2 min read